Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
48 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Retinal Degeneration - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Retinal Degeneration - Pipeline Review, H2 2014', provides an overview of the Retinal Degeneration's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Retinal Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Degeneration and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Retinal Degeneration - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinal Degeneration and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinal Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Retinal Degeneration pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Retinal Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Retinal Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Retinal Degeneration Overview 7 Therapeutics Development 8 Pipeline Products for Retinal Degeneration - Overview 8 Pipeline Products for Retinal Degeneration - Comparative Analysis 9 Retinal Degeneration - Therapeutics under Development by Companies 10 Retinal Degeneration - Therapeutics under Investigation by Universities/Institutes 11 Retinal Degeneration - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Retinal Degeneration - Products under Development by Companies 14 Retinal Degeneration - Products under Investigation by Universities/Institutes 15 Retinal Degeneration - Companies Involved in Therapeutics Development 16 AmpliPhi Biosciences Corporation 16 Aprogen, Inc. 17 BBB Therapeutics B.V. 18 GenSight Biologics 19 SanBio, Inc. 20 Senju Pharmaceutical Co., Ltd. 21 Spark Therapeutics, Inc. 22 Retinal Degeneration - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 AP-202 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 CB-11 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Gene Therapy for Choroideremia - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Gene Therapy for Retinal Degenerative Disease - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 SB-623 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecule 8 for Retinitis Pigmentosa - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules for Inherited Retinal Diseases - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 SNC-121 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 SNJ-1945 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Stem Cell Therapy for Cancer, Pain, Retinal Degeneration and Niemann-Pick Disease - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 tgAAG-76 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Retinal Degeneration - Recent Pipeline Updates 44 Retinal Degeneration - Dormant Projects 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 48 Disclaimer 48
List of Tables Number of Products under Development for Retinal Degeneration, H2 2014 8 Number of Products under Development for Retinal Degeneration - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Number of Products under Investigation by Universities/Institutes, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Retinal Degeneration - Pipeline by AmpliPhi Biosciences Corporation, H2 2014 16 Retinal Degeneration - Pipeline by Aprogen, Inc., H2 2014 17 Retinal Degeneration - Pipeline by BBB Therapeutics B.V., H2 2014 18 Retinal Degeneration - Pipeline by GenSight Biologics, H2 2014 19 Retinal Degeneration - Pipeline by SanBio, Inc., H2 2014 20 Retinal Degeneration - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2014 21 Retinal Degeneration - Pipeline by Spark Therapeutics, Inc., H2 2014 22 Assessment by Monotherapy Products, H2 2014 23 Number of Products by Stage and Target, H2 2014 25 Number of Products by Stage and Mechanism of Action, H2 2014 27 Number of Products by Stage and Route of Administration, H2 2014 29 Number of Products by Stage and Molecule Type, H2 2014 31 Retinal Degeneration Therapeutics - Recent Pipeline Updates, H2 2014 44 Retinal Degeneration - Dormant Projects, H2 2014 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.